BioMarin Q1 2026 slides: revenue beats offset by margin pressure

BioMarin beat Q1 2026 expectations with revenue of $766 million versus $755.94 million consensus and non-GAAP EPS of $0.76 versus $0.74, but shares fell after hours on margin pressure and acquisition-related dilution. Full-year revenue guidance was raised to $3.825 billion-$3.925 billion, while non-GAAP EPS guidance was trimmed to $4.85-$5.05 due to the Amicus acquisition, which is expected to be accretive only in 2027. Operating expenses rose sharply, with R&D up 13% to $179 million and SG&A up 25% to $258 million.

Analysis

BMRN’s print reads like a classic “good quarter, worse setup” inflection: the market is discounting not the beat, but the earnings power gap between now and when Amicus assets are fully digested. The second-order issue is mix deterioration in the near term — higher SG&A/R&D and acquisition-related friction can suppress consensus multiple expansion even if top-line acceleration arrives, because investors will demand evidence that new launches can offset integration drag before underwriting a rerating.

The key underappreciated catalyst is not the acquisition itself but the sequencing of the 2H calendar. Management has loaded most of the year’s revenue and earnings into 2H, which creates asymmetric downside if either VOXZOGO approval timing slips or BMN 401 data disappoints. In that setup, the stock behaves less like a steady rare-disease compounder and more like a binary catalyst chain; any miss could force estimate cuts into a period when margin recovery is already deferred to 2027.

From a competitive lens, the Amicus assets should intensify commercial focus in ultra-rare enzyme space, but the bigger implication is bargaining power: larger scale may improve payer leverage and field force efficiency, yet it also raises the hurdle for smaller competitors to win formulary access. The stronger balance sheet and free cash flow profile argue this is not a solvency story; it is a timing story. The contrarian read is that the selloff may be overdone if the market is pricing current-quarter margin compression as structural rather than transitory integration cost, especially with the stock near cycle lows and guidance still implying material revenue growth.

For FOLD, the strategic overlap creates a loser-by-acquisition-dynamics effect: even without direct product displacement, BioMarin’s scale-up could pressure Amicus’ future commercial narrative and make independent valuation harder to sustain if payer/physician attention shifts toward the combined BioMarin platform.

Key Decisions for Investors

• Long BMRN on weakness, sized as a 3-6 month catalyst trade: use a staged entry near the post-earnings fade with a target of a re-rating into BMN 401 / VOXZOGO data. Risk/reward is attractive if the market is over-penalizing temporary margin compression; stop if 2H guidance credibility deteriorates.
• Buy BMRN call spreads over the next 3-5 months to express upside from binary clinical catalysts while limiting downside from integration noise. Prefer structures that monetize a data-driven rerating rather than outright delta exposure.
• Short FOLD as a relative value hedge against BioMarin’s enlarged enzyme-therapy footprint over 6-12 months. The thesis is not immediate product cannibalization, but a slower erosion of independent growth optionality and investor attention within the same rare-disease set.
• Pair trade: long BMRN / short a broader profitable-biotech basket for the next quarter. The name-specific catalysts provide idiosyncratic upside, while the short leg hedges sector multiple compression if rates/biotech risk appetite deteriorate.
• If BMRN rallies into the catalyst window without data confirmation, take partial profits into strength. The market is likely to reward proof of operating leverage more than guidance alone, and that proof likely won’t arrive until late 2026 or 2027.